X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The funding aims to support Immuron advance their clinical development of Travelan (bovine colostrum), which is being evaluated in Phase II clinical trial studies for the treatment of moderate to severe diarrhea.
Lead Product(s): Bovine Colostrum
Therapeutic Area: Gastroenterology Product Name: Travelan
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: U.S. Department of Defense
Deal Size: $3.4 million Upfront Cash: Undisclosed
Deal Type: Funding March 07, 2024
Details:
Immuron vaccine drug candidate CampETEC, which is being evaluating for the diarrhoea caused by Campylobacter and including Enterotoxigenic Escherichia coli infections.
Lead Product(s): CampETEC
Therapeutic Area: Gastroenterology Product Name: CampETEC
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: US Naval Medical Research Command
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 04, 2023
Details:
Travelan (bovine colostrum) is an oral biopharmaceutical product that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) tract, to prevent infectious diarrhea caused by enterotoxigenic Escherichia coli (ETEC).
Lead Product(s): Bovine Colostrum
Therapeutic Area: Infections and Infectious Diseases Product Name: Travelan
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2023
Details:
Travelan (bovine colostrum) is an oral biopharmaceutical product that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) tract, to prevent infectious diarrhea caused by enterotoxigenic Escherichia coli (ETEC).
Lead Product(s): Bovine Colostrum
Therapeutic Area: Infections and Infectious Diseases Product Name: Travelan
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 25, 2023
Details:
Travelan (bovine colostrum) is an oral biopharmaceutical product that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) tract, to prevent infectious diarrhea caused by enterotoxigenic Escherichia coli (ETEC).
Lead Product(s): Bovine Colostrum
Therapeutic Area: Infections and Infectious Diseases Product Name: Travelan
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 30, 2023
Details:
CampETEC is a new therapeutic developed in collaboration with NMRC. Two Phase Il clinical studies are planned to evaluate safety and clinical efficacy against infectious diarrhea caused by Campylobacter and ETEC.
Lead Product(s): CampETEC
Therapeutic Area: Gastroenterology Product Name: CampETEC
Highest Development Status: IND EnablingProduct Type: Small molecule
Recipient: Naval Medical Research Center
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 08, 2023
Details:
The Naval Medical Research Center (NMRC) has executed a research agreement with Immuron to develop and clinically evaluate a new therapeutic CampETEC, targeting Campylobacter and ETEC infections.
Lead Product(s): CampETEC
Therapeutic Area: Gastroenterology Product Name: CampETEC
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2023
Details:
IMM-529 is a polyclonal antibody biological product which prevents and treats Clostridioides difficile infections and has been developed to spare the gut microbiome from the effects of "classic" antibiotic treatments by neutralising localized toxin B at the site of infection.
Lead Product(s): Polyclonal Antibody
Therapeutic Area: Infections and Infectious Diseases Product Name: IMM-529
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2023
Details:
The Investigational New Drug (IND) application to evaluate the efficacy of a single dose of Travelan (bovine colostrum) to prevent infectious diarrhea caused by ETEC is now active.
Lead Product(s): Bovine Colostrum
Therapeutic Area: Infections and Infectious Diseases Product Name: Travelan
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 23, 2022
Details:
Travelan (bovine colostrum) is an over the counter immune supplement that can be taken to reduce the risk of diarrhoea and reduce the symptoms of minor gastrointestinal disorders. Travelan® helps to support a healthy digestive system by supporting the gut’s immune defences.
Lead Product(s): Bovine Colostrum
Therapeutic Area: Infections and Infectious Diseases Product Name: Travelan
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
